Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072-7. doi: 10.1016/S0140-6736(02)08905-5.
Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:25-30. doi: 10.4158/EP.12.S1.25.
Pasiechko NV, Loy NYa, Mazur LP, Savchenko IP. The efficiency of using α-glucosidase inhibitors in patients with diabetes mellitus type 2 and obesity. Mìžnarodnij endokrinologìčnij žurnal. 2015;2(66):75-78. doi: 10.22141/2224-07220.127.116.115.75444. (in Ukrainian).
Pasiechko NV, Naumova LV, Skrypnyk NV, Svystun II, Golyk IV. The efficiency of using Siofor in patients with obesity and hyperinsulinism on the stage of prediabetes. Mìžnarodnij endokrinologìčnij žurnal. 2012;2(42):83-86. (in Ukrainian).
Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607-14. doi: 10.1016/S0140-6736(09)60222-1.
Cherniavska IV. Profile of cardiovascular risk factors in ischemic heart disease in patients with normal and impaired carbohydrate metabolism. Mìžnarodnij endokrinologìčnij žurnal. 2016;3(75):27-31. doi: 10.22141/2224-0718.104.22.1686.76627. (in Ukrainian).
Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28(1):154-163. PMID: 15616251.
Holman RR. Acarbose Cardiovasular Evaluation (ACE): primary results. In: Proceeding of the 53rd Annual Meeting of the European Association for the Study of Diabetes. 2017 Sep 11-15; Lisbon, Portugal.
Pankiv VI. Impact of voglibose on metabolic control indicators in patients with diabetes mellitus type 1. Mìžnarodnij endokrinologìčnij žurnal. 2015;1(65):33-7. doi: 10.22141/2224-0722.214.171.1245.75889. (in Ukrainian).
Pankiv VI. Preventive and therapeutic effect of voglibose in management of diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2014;5(61):83-87. doi: 10.22141/2224-07126.96.36.1994.76860. (in Ukrainian).
Pankiv VI. New therapeutic possibilities of type 2 diabetes mellitus management: experience of voglibose application. Mìžnarodnij endokrinologìčnij žurnal. 2014;6(62):51-54. doi: 10.22141/2224-07188.8.131.524.76937. (in Ukrainian).
Pankiv VI, Cherniavska IV. Choice of method for type 2 diabetes mellitus prevention: as pathogenetic approach using voglibose. Mìžnarodnij endokrinologìčnij žurnal. 2014;7(63):45-49. doi: 10.22141/2224-07184.108.40.2064.77127. (in Ukrainian).
Pankiv VI. Inhibitor of α-glucosidase voglibose: new possibilities of treatment and prevention of diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2013;7(55):35-38. doi: 10.22141/2224-07220.127.116.113.84676 (in Ukrainian).
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS.